Mapi - Pharma (Mapi - Pharma) 3-Year Dividend Growth Rate : 0.00% (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma 3-Year Dividend Growth Rate?

Mapi - Pharma's Dividends per Share for the six months ended in Jun. 2015 was $0.00.

The historical rank and industry rank for Mapi - Pharma's 3-Year Dividend Growth Rate or its related term are showing as below:

MAPI's 3-Year Dividend Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 10.8
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Mapi - Pharma's Dividend Payout Ratio for the six months ended in Jun. 2015 was 0.00. As of today, Mapi - Pharma's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Mapi - Pharma's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's 3-Year Dividend Growth Rate falls into.

Mapi - Pharma 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Mapi - Pharma (NAS:MAPI) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Mapi - Pharma's Dividend Payout Ratio for the quarter that ended in Jun. 2015 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2015 )	/	EPS without NRI (Q: Jun. 2015 )
	=	0	/	-0.25
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mapi - Pharma 3-Year Dividend Growth Rate Related Terms>

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.